Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speakers will provide an introduction to the alliance of radiopharmaceutical experts in the development of theranostic radiopharmaceuticals. The webinar will feature innovations from each partner in the alliance, from target identification to clinical radiopharmaceutical development. Attendees will learn about the advantages of a premium nuclear medicine solution for drug discovery and theranostic programs, and an integrated strategy for preclinical and clinical drug development plans.
TORONTO, Oct. 21, 2021 /PRNewswire-PRWeb/ -- Preclinical and clinical evaluation of radiopharmaceuticals can be sometimes seen as straightforward compared to non-radioactive molecules as the injected doses are often below toxic doses. However, the development of theranostics requires highly specific expertise and strong collaboration between preclinical and clinical development.
The DRIVE™-Molecular RadioTherapy (MRT) offer is based on the complementary knowledge and know-how of each partner (Covalab, CheMatech, ABX-CRO and Oncodesign) representing an experienced and innovative network in nuclear medicine. The four companies have built a joint value proposition in which the generation of radiolabeled biological vectors, chelator production, design of the bioconjugated lead, preclinical proof of concept and the design of the regulatory and clinical package are managed effectively and efficiently under one roof.
This webinar will explore their key expertise with a focus on innovations from each partner, as follows:
- Covalab— development and production of custom antibodies, antibody fragments and site-specific conjugation
- CheMatech— custom design, synthesis and GMP production of chelators
- Oncodesign— target identification and generation of preclinical radiopharmaceutical drug candidates
- ABX-CRO — IMP radiochemistry development; dosimetry and regulatory preclinical package; clinical project management; data management and biostatistics; and integrated clinical and imaging study design
Join this webinar to learn about how the DRIVE-MRT solution enables the rationalization, design and optimization of targeted and effective radiopharmaceuticals against specific cancers, with a demonstration of preclinical proof of acceptable safety margins and a clinical support plan.
Join Dr. Meddy El Alaoui, CSO, Covalab; Dr. Frederic Boschetti, CEO, CheMatech; Dr. Cyril Berthet, Head of Pharmaco-Imaging and Molecular Radiotherapy Department, Oncodesign; and Dr. Andreas Kluge, General Manager, ABX-CRO, for the live webinar on Friday, November 5, 2021 at 11am EDT (3pm GMT/UK).
For more information, or to register for this event, visit Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]
SOURCE Xtalks
Share this article